CUHK Professor Elaine Chow Receives “2022 Women’s Interprofessional Network of the American Diabetes Association Abstract Award” for Outstanding Research and Care in Diabetes

HONG KONG, Jun 5, 2022 - (ACN Newswire via SEAPRWire.com) - Professor Elaine YK Chow from the Faculty of Medicine at The Chinese University of Hong Kong has received the "2022 Women's Interprofessional Network of the American Diabetes Association Abstract Award" in the category of Clinical Diabetes, Epidemiology, and Diabetes...

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels

       - First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics -        - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN DIEGO and SUZHOU, China, May 26, 2022...

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

SHANGHAI, CHINA, May 13, 2022 - (ACN Newswire via SEAPRWire.com) - Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational...

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trialsANB032 IND filing in an initial proof-of-concept Phase 2 trial is anticipated in the second half of 2022Imsidolimab (anti-IL-36R Ab) top-line data from the Phase 2...

First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio

Committee members include globally renowned experts in gastrointestinal diseases, including ulcerative colitis and Crohn’s diseaseBOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI)...

SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA

HONG KONG, Apr 20, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased...

Avance Clinical進入Informa Pharma Intelligence 2022年亞太地區最佳CRO最終候選名單

ADELAIDE, AUS, Apr 19, 2022 - (亞太商訊 via SEAPRWire.com) - Avance Clinical是澳大利亞本地最大的CRO,致力於協助世界各地的生物科技及製藥公司完成早期臨床研究。今年Avance Clinical進入了Informa Pharma Intelligence 2022年亞太地區最佳CRO最終候選名單。近年來,Avance Clinical 發展迅速,最近在墨爾本和悉尼都開設了新辦公室以支持其日益壯大的臨床運營團隊。該獎項的最終獲得者將於2022年9月1日公佈。目前的候選企業包括:- Avance Clinical- Calyx- CMIC Group- EPS- ICON- Parexel- Syneos HealthAvance Clinical的首席執行官Yvonne Lungershausen表示,“Avance Clinical能夠進入到如此有聲望的一個獎項的最終候選名單,我們感到非常榮幸。這是Informa Pharma Intelligence的評委們對以客戶為本的Avance Clinical團隊的肯定,也是對我們提供的CRO服務質量的肯定。Avance Clinical在全球久負盛名,因為我們能為生物科技公司提供靈活的解決方案,加速臨床研發進度。我們對於公司近年來在亞太地區的發展以及取得的成就感到非常自豪。”根據Informa Pharma Intelligence的標準:該獎項的設立是為了表彰在日本以及亞洲其他地區包括澳大利亞的一站式CRO服務公司。評委們會考量CRO公司的服務質量,客戶關係及受試者招募的創新度。該獎項的評定標準是基於2021年各個CRO公司取得的成就。核心評審標準包括:- CRO公司的獨特優勢和能力- CRO公司如何超出申辦方預期的完成相關任務- CRO公司在受試者招募戰略方面的創新度- CRO公司如何提高業務質量,如:數據質量,時間線及透明度- CRO公司在統一數據收集和匯報方面的流程更多信息請訪問: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022Avance Clinical最近與國際私募基金公司The Riverside Company達成了的合作協議,以支持其地區性和全球性的業務拓展,該合作使Avance Clinical的估值超過2億澳元。首席執行官Yvonne表示,“有了具有國際合作經驗以及在醫療健康領域有深度見解的Riverside的支持,Avance Clinical將通過收購的方式實現地區性以及全球性的擴展。”Avance Clinical是一家澳大利亞本土CRO公司,致力於為本地以及國際生物製藥公司提供符合國際標準的臨床研究服務,服務範圍橫跨各個臨床研究階段。同時,Avance Clinical也是一家被澳大利亞基因科技監管辦公室(OGTR)認證的基因科技CRO,這使其有資格進行疫苗以及基因修飾生物體相關的臨床研究。首席執行官Yvonne談到,“我們有著非常高的回頭業務率,這足以證明我們的技術以及以客戶為本的臨床專家可以在快節奏和強競爭的環境中脫穎而出,滿足我們客戶的需求。”Avance...

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

ADELAIDE, AUS, Apr 19, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence.Avance Clinical has undergone significant expansion in recent years,...

Avance Clinical Announces New Office Opening in Melbourne

MELBOURNE, Mar 31, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Melbourne to support its growing clinical team in the greater Melbourne region.The Avance Clinical team in MelbourneThe formal opening event was attended...

Essex Bio-Technology Announces 2021 Financial Results

HONG KONG, Mar 22, 2022 - (ACN Newswire via SEAPRWire.com) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.Highlights-- The group's turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million;-- Sales coverage increased...

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting

TOKYO, Mar 11, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022...